$HUTCHMED(00013)$ The biotech

$HUTCHMED(00013)$ The biotech sector is experiencing a valuation re-rating, with industry leaders like HUTCHMED and $INNOVENT BIO(01801)$ leading the way.

This year marks a turning point, not just for the broader Hong Kong stock market but also for innovative drugmakers. While much attention has been on Hang Seng Tech and Internet sectors, the Hong Kong Biotech ETF (SZ159570) has surged 32% year-to-date, significantly outperforming tech and internet ETFs.

Positive catalysts such as improving drug procurement policies, booming License out deals from major players like Hengrui, and Innovent’s stellar earnings report have fueled this rally. With Hong Kong-listed biotech stocks showing stronger rebounds due to deeper previous corrections, now is the time to seize the investment opportunity in innovative medicine!

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":418363549536640,"tweetId":"418363549536640","gmtCreate":1743147334501,"gmtModify":1743148190336,"author":{"id":9000000000000661,"idStr":"9000000000000661","authorId":9000000000000661,"authorIdStr":"9000000000000661","name":"CareyDunlop","avatar":"https://static.tigerbbs.com/742a1a3fe6754169c97157f6d9276916","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/54ac87d20b7a588ee16e944df8676ea6","width":"767","height":"1280"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/54ac87d20b7a588ee16e944df8676ea6","width":"767","height":"1280"}],"html":"<html><head></head><body> <a data-mention-id=\"00013\" class=\"teditor-mention\" data-mention-name=\"HUTCHMED\" href=\"https://ttm.financial/S/00013\">$HUTCHMED(00013)$</a> The biotech sector is experiencing a valuation re-rating, with industry leaders like HUTCHMED and <a data-mention-id=\"01801\" class=\"teditor-mention\" data-mention-name=\"INNOVENT BIO\" href=\"https://ttm.financial/S/01801\">$INNOVENT BIO(01801)$</a> leading the way. This year marks a turning point, not just for the broader Hong Kong stock market but also for innovative drugmakers. While much attention has been on Hang Seng Tech and Internet sectors, the Hong Kong Biotech ETF (SZ159570) has surged 32% year-to-date, significantly outperforming tech and internet ETFs. Positive catalysts such as improving drug procurement policies, booming License out deals from major players like Hengrui, and Innovent’s stellar earnings report have fueled this rally. With Hong Kong-listed biotech stocks showing stronger rebounds due to deeper previous corrections, now is the time to seize the investment opportunity in innovative medicine!<img src=\"https://community-static.tradeup.com/news/54ac87d20b7a588ee16e944df8676ea6\" tg-width=\"767\" tg-height=\"1280\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"00013\" class=\"teditor-mention\" data-mention-name=\"HUTCHMED\" href=\"https://ttm.financial/S/00013\">$HUTCHMED(00013)$</a> The biotech sector is experiencing a valuation re-rating, with industry leaders like HUTCHMED and <a data-mention-id=\"01801\" class=\"teditor-mention\" data-mention-name=\"INNOVENT BIO\" href=\"https://ttm.financial/S/01801\">$INNOVENT BIO(01801)$</a> leading the way. This year marks a turning point, not just for the broader Hong Kong stock market but also for innovative drugmakers. While much attention has been on Hang Seng Tech and Internet sectors, the Hong Kong Biotech ETF (SZ159570) has surged 32% year-to-date, significantly outperforming tech and internet ETFs. Positive catalysts such as improving drug procurement policies, booming License out deals from major players like Hengrui, and Innovent’s stellar earnings report have fueled this rally. With Hong Kong-listed biotech stocks showing stronger rebounds due to deeper previous corrections, now is the time to seize the investment opportunity in innovative medicine!<img src=\"https://community-static.tradeup.com/news/54ac87d20b7a588ee16e944df8676ea6\" tg-width=\"767\" tg-height=\"1280\"></body></html>","text":"$HUTCHMED(00013)$ The biotech sector is experiencing a valuation re-rating, with industry leaders like HUTCHMED and $INNOVENT BIO(01801)$ leading the way. This year marks a turning point, not just for the broader Hong Kong stock market but also for innovative drugmakers. While much attention has been on Hang Seng Tech and Internet sectors, the Hong Kong Biotech ETF (SZ159570) has surged 32% year-to-date, significantly outperforming tech and internet ETFs. Positive catalysts such as improving drug procurement policies, booming License out deals from major players like Hengrui, and Innovent’s stellar earnings report have fueled this rally. With Hong Kong-listed biotech stocks showing stronger rebounds due to deeper previous corrections, now is the time to seize the investment opportunity in innovative medicine!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/418363549536640","repostId":0,"isVote":1,"tweetType":1,"viewCount":1920,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["01801","00013"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":702,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/418363549536640"}